Cart
sales@molnova.com
GS87
CAS No. 919936-70-2
GS87( 4-[5-[[(3-Phenyl-1,2,4-oxadiazol-5-yl)methyl]thio]-1,3,4-oxadiazol-2-yl]pyridine )
Catalog No. M22248 CAS No. 919936-70-2
GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 179 | In Stock |
|
| 5MG | 169 | In Stock |
|
| 10MG | 258 | In Stock |
|
| 25MG | 426 | In Stock |
|
| 50MG | 586 | In Stock |
|
| 100MG | 792 | In Stock |
|
| 200MG | 1051 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGS87
-
NoteResearch use only, not for human use.
-
Brief DescriptionGS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells.
-
DescriptionGS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells
-
In Vitro——
-
In Vivo——
-
Synonyms4-[5-[[(3-Phenyl-1,2,4-oxadiazol-5-yl)methyl]thio]-1,3,4-oxadiazol-2-yl]pyridine
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorGSK-3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number919936-70-2
-
Formula Weight337.36
-
Molecular FormulaC16H11N5O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC([S]c1nnc(o1)c2ccncc2)c3nc(no3)c4ccccc4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sophia, Hu, Masumi, et al. A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.[J]. Molecular Cancer Therapeutics, 2016.
molnova catalog
related products
-
KY19382
KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β( IC50s of 19 and 10 nM, respectively).
-
Dihydroergotoxine me...
It is mainly used to improve symptoms and physical symptoms of mental degeneration related to aging.
-
GSK3β-IN-1a
GSK3β-IN-1a is a relatively selective and potent GSK-3β inhibitor with IC50 of 64 nM.
